Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

BACKGROUND: With the development of new direct acting antiviral (DAA) therapy for hepatitis C, the backbone peginterferon alpha used may be of importance in maximizing treatment outcomes. To this end, the rates of sustained virologic response (SVR), relapse, and treatment discontinuation among hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Druyts, Eric, Mills, Edward J, Nachega, Jean, O’Regan, Christopher, Cooper, Curtis L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304330/
https://www.ncbi.nlm.nih.gov/pubmed/22427726
http://dx.doi.org/10.2147/CEG.S28253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304330/
https://www.ncbi.nlm.nih.gov/pubmed/22427726
http://dx.doi.org/10.2147/CEG.S28253

Ejemplares similares